These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Graves-Basedow type ophthalmopathy and primary hypothyroidism]. Cathelineau G; Fribourg-Desi M Nouv Presse Med; 1974 Sep; 3(32):1995-8. PubMed ID: 4372586 [No Abstract] [Full Text] [Related]
6. Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies. Pinchera A; Liberti P; Martino E; Fenzi GF; Grasso L; Rovis L; Baschieri L; Doria G J Clin Endocrinol Metab; 1969 Feb; 29(2):231-8. PubMed ID: 4179303 [No Abstract] [Full Text] [Related]
7. [Effect of prednisone in immunosuppressive dosage on the clinical course of eye changes and dynamics of LATS titer in the serum]. Nauman J; Nauman A Pol Arch Med Wewn; 1973 May; 50(5):449-58. PubMed ID: 4740191 [No Abstract] [Full Text] [Related]
8. [Concept of endocrine ophthalmopathies]. Heberting HJ; Schwarzmann E Z Gesamte Inn Med; 1974 Sep; 29(17):712-5. PubMed ID: 4141190 [No Abstract] [Full Text] [Related]
9. [Influence of triiodothyronine on cervical lymphoid structures, thyroid activity and exophthalmos in Basedow's disease]. Mahaux JE; Chamla-Soumenkoff J; Nagel N; Levin S Rev Iber Endocrinol; 1968; 15(90):591-9. PubMed ID: 4180471 [No Abstract] [Full Text] [Related]
10. The eye changes of Graves' disease: overview. Werner SC Mayo Clin Proc; 1972 Dec; 47(12):969-74. PubMed ID: 4564711 [No Abstract] [Full Text] [Related]
11. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Perros P; Weightman DR; Crombie AL; Kendall-Taylor P Acta Endocrinol (Copenh); 1990 Jan; 122(1):8-12. PubMed ID: 2305608 [TBL] [Abstract][Full Text] [Related]
12. [Step-by-step treatment of progressive edematous-infiltrative ophthalmopathy in Graves' disease. Results of the first stage of treatment with glucocorticoids and glucocorticoids with azathioprine]. Pilarska K; Czekalski S; Syrenicz A; Andrzejewska W; Krzystolik Z; Przerwa D; Daniel B Endokrynol Pol; 1988; 39(5):229-36. PubMed ID: 3076562 [No Abstract] [Full Text] [Related]
13. Management of the active severe eye changes of Graves' disease. Werner SC Trans Am Acad Ophthalmol Otolaryngol; 1967; 71(4):631-7. PubMed ID: 6072401 [No Abstract] [Full Text] [Related]
14. Relapse of Graves' disease 23 years after treatment with radioactive iodine (131I). Hegele RA; Volpé R J Clin Lab Immunol; 1985 Oct; 18(2):103-5. PubMed ID: 3841162 [TBL] [Abstract][Full Text] [Related]
15. [On the anti-exophthalmic and anti-thyroid action of an imidazole derivative with trichomonacidal action: metronidazole]. Portioli I; Rocchi F; Maraini G; Pescatori A Ann Ottalmol Clin Ocul; 1968 Dec; 94(12):1457-73. PubMed ID: 5757142 [No Abstract] [Full Text] [Related]
16. Studies on the pathogenesis of the ophthalmopathy of Graves' disease. Kriss JP; Pleshakov V; Rosenblum AL; Holderness M; Sharp G; Utiger R J Clin Endocrinol Metab; 1967 Apr; 27(4):582-93. PubMed ID: 6071430 [No Abstract] [Full Text] [Related]
17. What the internist should know about the ophthalmopathy of Graves' disease. Hamburger JI; Sugar HS Arch Intern Med; 1972 Jan; 129(1):131-9. PubMed ID: 5066655 [No Abstract] [Full Text] [Related]
18. Spontaneous reversal of vertical diplopia in Graves' eye disease. Frueh BR; Benger RS Trans Am Ophthalmol Soc; 1985; 83():387-96. PubMed ID: 3841699 [No Abstract] [Full Text] [Related]
20. [Assessment of early immunosuppressive therapy in the prevention of complications of Graves' disease]. Huszno B; Trofimiuk M; Gołkowski F; Plinta T; Szybiński Z Przegl Lek; 2004; 61(8):868-71. PubMed ID: 15789920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]